Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate
Conclusion
TCZ is a cost-effective therapeutic option compared to other tumor necrosis factor-α inhibitors (ADA, ETA, CTZ) as first-line monotherapy for patients who are intolerant to MTX, or for whom it is inappropriate to continue treatment with MTX.
Funding
Roche SpA.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Actemra | Arthritis | Drugs & Pharmacology | Enbrel | Humira | Methotrexate | Rheumatoid Arthritis | Rheumatology